Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer
Status:
Not yet recruiting
Trial end date:
2026-10-24
Target enrollment:
Participant gender:
Summary
This is a two arm, 2-center, Phase II, study of 5-FU, irinotecan, bevacizumab (FOLFIRI-beva)
and hydroxychloroquine (HCQ) in patients with previously untreated metastatic colorectal
cancer (mCRC).
Up to 155 patients will be screened for DTP-signature and up to 31 evaluable patients who are
determined to be DTP-signature high will be treated with FOLFIRI-beva and HCQ.
Patients will continue to receive treatments until evidence of disease progression,
intolerable side effects, withdrawal of consent or death.